Enhancing ARIC Infrastructure to Yield a New Cancer Epidemiology Cohort

加强 ARIC 基础设施以产生新的癌症流行病学队列

基本信息

批准号：
8469418
负责人：
ELIZABETH A. PLATZ
金额：
$ 55.63万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-05-15 至 2017-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8469418
关键词：
Address African American Archives Area Arts Atherosclerosis Authorization documentation Award Biological Markers Blood Blood specimen Breast Cancer Research Infrastructure Cessation of life Clinical Colon Communities Consent Contracts Cost Savings DNA Sequence Data Death Certificates Diabetes Mellitus Diagnosis Discipline Epidemiologic Studies Epidemiologist Female Female breast Food Frequencies Funding Handedness Head Health Histology Hospitalization Hospitals Incidence Instruction Interview Life Style Link Location Malignant Neoplasms Malignant neoplasm of lung Measurement Measures Medical Medical Records Medicare Molecular Genetics National Heart, Lung, and Blood Institute Natural History Operative Surgical Procedures Organ Paper Participant Pathologic Pathology Pharmaceutical Preparations Prostate Protocols documentation Publishing Questionnaires Recontacts Records Recruitment Activity Recurrence Registries Research Research Infrastructure Research Personnel Resected Resources Retreatment Risk Schedule Site Specimen Staging Telephone Time Tissue Microarray Tissues Update Urine Variant Visit Washington Woman Work abstracting adjudicate aged anticancer research cancer diagnosis cancer epidemiology cancer recurrence cancer surgery cohort cost fasting glucose follow-up genome sequencing genome wide association study interest mortality neoplasm registry novel operation receptor response risk variant tissue processing working group

项目摘要

DESCRIPTION (provided by applicant): We propose to enhance the infrastructure of ARIC; the Atherosclerosis Risk in Communities, cohort to yield a new Cancer Epidemiology Cohort that brings novel features to cancer epidemiology research. In 1987, 15,792 participants aged 45-64 years were recruited from Forsyth Co., NC; Jackson, MS; Minneapolis, MN; and Washington Co., MD. 55% are women and 27% are African-American. Participants underwent 4 clinical exams; a 5th is scheduled for 2011. Blood and urine specimens have been banked, medications recorded, and a food frequency questionnaire completed. Participants were interviewed by phone annually and now semi-annually to obtain updated health information. The response at year 21 is 91%. Because ARIC has never been viewed as a Cancer Epidemiology Cohort and infrastructure and cost constraints, only cancer diagnosis has been systematically recorded. By 2006, 3,145 participants were diagnosed with an incident first primary and 376 with a 2nd / 3rd primary. Information, such as stage, grade, and histology, location in organ, laterality, receptor status, treatment, recurrence, and re-treatment, needed to address contemporary questions is not currently available. Tissue needed for molecular/genetic studies has not been collected. Thus, we propose: 1) Starting 2012, to prospectively identify cases from semi-annual phone interviews and collect medical/pathology records pertaining to cancer diagnosis, treatment, recurrence, and retreatment and tissue blocks. 2) To retrospectively collect information characterizing cancer diagnoses and recurrences before 2012 from cancer registries in the 4 ARIC states (consent already obtained) and medical records, and collect tissue blocks. By 2016, we expect 4,900 fully annotated incident cases. We established a Cancer Working Group to develop protocols for adjudicating cancer endpoints and prioritize research using the resource. With enhanced infrastructure, we expect that research questions such as these are addressable uniquely in ARIC: 1) What is the association between timing of the natural history of diabetes using 4 fasting glucose and 2 HbAlc measurements and timing of cancer diagnosis? 2) Using GWAS and sequencing data, is there a set of risk variants shared by major cancers or are variants specific to each site?

描述（由申请人提供）：我们建议加强 ARIC 的基础设施；社区动脉粥样硬化风险队列将产生一个新的癌症流行病学队列，为癌症流行病学研究带来新特征。 1987年，从北卡罗来纳州福赛思公司招募了15,792名年龄在45-64岁之间的参与者；杰克逊，MS；明尼苏达州明尼阿波利斯；和华盛顿公司，MD。 55% 是女性，27% 是非裔美国人。参与者接受了4次临床检查； a 计划于 2011 年进行第 5 次。血液和尿液样本已存入库，记录了用药情况，并完成了食物频率调查问卷。参与者每年接受一次电话采访，现在每半年接受一次电话采访，以获取最新的健康信息。第 21 年的响应率为 91%。由于 ARIC 从未被视为癌症流行病学队列以及基础设施和成本限制，因此仅系统记录了癌症诊断。到 2006 年，有 3,145 名参与者被诊断出患有第一原发性疾病，376 名参与者被诊断出患有第二/第三原发性疾病。目前尚无法获得解决当代问题所需的信息，例如分期、分级和组织学、器官位置、偏侧性、受体状态、治疗、复发和再治疗。尚未收集分子/遗传学研究所需的组织。因此，我们建议：1）从2012年开始，通过每半年的电话访谈前瞻性地识别病例，收集与癌症诊断、治疗、复发、再治疗和组织块有关的医学/病理记录。 2）从4个ARIC州的癌症登记处（已获得同意）和医疗记录中回顾性收集2012年之前癌症诊断和复发的信息，并收集组织块。到 2016 年，我们预计将有 4,900 个带有完整注释的事件案例。我们成立了一个癌症工作组来制定判定癌症终点的方案并优先考虑使用该资源的研究。随着基础设施的增强，我们预计这些研究问题可以在 ARIC 中得到独特解决：1) 使用 4 项空腹血糖和 2 项 HbAlc 测量来确定糖尿病自然史的时间与癌症诊断的时间之间有何关联？ 2) 使用 GWAS 和测序数据，是否存在主要癌症共有的一组风险变异，或者每个位点都有特定的变异？